The new guidance, published by the MHRA alongside international regulatory authorities from Australia, Canada, Singapore and Switzerland, details what information is required to approve modifications to authorised COVID-19 vaccines.
Although ‘time-consuming’ clinical studies won’t be needed, vaccine makers will need to provide robust evidence that an updated vaccine produces an immune response against a new variant.
